C

Cytosorbents Corp

CTSO

1.13000
USD
-0.06
(-5.04%)
مغلق
حجم التداول
617
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
56,062,506
أصول ذات صلة
A
ADMP
0
(0%)
0.000000 USD
B
BCRX
-0.19000
(-2.61%)
7.10000 USD
D
DVAX
-0.280
(-2.50%)
10.910 USD
الأخبار المقالات

العنوان: Cytosorbents Corp

القطاع: Healthcare
الصناعة: Medical Devices
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.